HIIFS
BLRX

Harel Insurance Investments & Financial Services’s BioLineRX BLRX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-58
Closed -$30K – 465
2018
Q1 		$30K Sell
58
-8
-12% -$4.9K ﹤0.01% 352
2017
Q4 		$43K Sell
66
-72
-52% -$47.4K ﹤0.01% 343
2017
Q3 		$93K Sell
138
-42
-23% -$26.1K 0.01% 235
2017
Q2 		$91K Buy
180
+126
+233% +$64.8K 0.01% 244
2017
Q1 		$29K Buy
+54
New +$34.8K ﹤0.01% 290

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harel Insurance Investments & Financial Services's BLRX Position: Q2 2018 in Review

Harel Insurance Investments & Financial Services sold out of BioLineRX (BLRX) in Q2 2018, closing a stake of 58 shares — an estimated $30K sold.

Harel Insurance Investments & Financial Services first reported a position in BLRX in Q1 2017 and held it in 5 quarters. The position peaked at $93K in Q3 2017. 25 funds tracked by Wall St. Rank hold BLRX as of Q2 2018.

  • Harel Insurance Investments & Financial Services reported no remaining BioLineRX position as of Q2 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 58 BioLineRX shares in Q2 2018, an estimated $30K.
  • Harel Insurance Investments & Financial Services first reported a position in BioLineRX in Q1 2017 and held it in 5 quarters.
  • Harel Insurance Investments & Financial Services's BioLineRX position peaked at $93K in Q3 2017.
  • 25 funds tracked by Wall St. Rank held BioLineRX as of Q2 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2018, filed 30 Jul 2018.